S'abonner

Clinical and virological data of the first cases of COVID-19 in Europe: a case series - 08/06/20

Doi : 10.1016/S1473-3099(20)30200-0 
Francois-Xavier Lescure, ProfMD a, g, , Lila Bouadma, ProfMD b, g, , Duc Nguyen, MD h, k, Marion Parisey, MD a, Paul-Henri Wicky, MD b, g, Sylvie Behillil, PharmD i, Alexandre Gaymard, PharmD l, m, Maude Bouscambert-Duchamp, PharmD l, m, Flora Donati, MSc i, Quentin Le Hingrat, PhD c, g, Vincent Enouf, PhD i, j, Nadhira Houhou-Fidouh, PharmD c, Martine Valette, PharmD l, m, Alexandra Mailles, PhD n, Jean-Christophe Lucet, ProfMD d, g, France Mentre, ProfPhD e, g, Xavier Duval, ProfMD f, g, Diane Descamps, ProfMD c, g, Denis Malvy, ProfMD h, k, Jean-François Timsit, ProfMD b, g, Bruno Lina, ProfMD l, m, , Sylvie van-der-Werf, ProfPhD i, , Yazdan Yazdanpanah, ProfMD a, g, ,
a Department of Infectious and Tropical Diseases, Assistance Publique—Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France 
b Medical and Infectious Diseases Intensive Care Unit, Assistance Publique—Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France 
c Department of Virology, Assistance Publique—Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France 
d Infection Control Unit, Assistance Publique—Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France 
e Department of Epidemiology, Biostatistics and Clinical Research, Assistance Publique—Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France 
f Center for Clinical Investigation, Assistance Publique—Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France 
g Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France 
h Department of Infectious Diseases and Tropical Medicine, University Hospital of Bordeaux, Bordeaux, France 
i National Reference Center for Respiratory Viruses, Molecular Genetics of RNA Viruses, CNRS—UMR 3569, The Institut Pasteur, Paris, France 
j Mutualized Platform of Microbiology, Pasteur International Bioresources Network, The Institut Pasteur, Paris, France 
k INSERM U1219, University of Bordeaux, Bordeaux, France 
l National Reference Center for Respiratory Viruses, Department of Virology, Infective Agents Institute, North Hospital Network, Lyon, France 
m Virpath Laboratory, International Center of Research in Infectiology, INSERM U1111, CNRS—UMR 5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon, Lyon University, Lyon, France 
n Santé Publique France, Saint Maurice, France 

* Correspondence to: Prof Yazdan Yazdanpanah, Department of Infectious and Tropical Diseases, Assistance Publique—Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018 Paris, France Department of Infectious and Tropical Diseases Assistance Publique—Hôpitaux de Paris Bichat-Claude Bernard University Hospital Paris 75018 France

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Background

On Dec 31, 2019, China reported a cluster of cases of pneumonia in people at Wuhan, Hubei Province. The responsible pathogen is a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the relevant features of the first cases in Europe of confirmed infection, named coronavirus disease 2019 (COVID-19), with the first patient diagnosed with the disease on Jan 24, 2020.

Methods

In this case series, we followed five patients admitted to Bichat-Claude Bernard University Hospital (Paris, France) and Pellegrin University Hospital (Bordeaux, France) and diagnosed with COVID-19 by semi-quantitative RT-PCR on nasopharyngeal swabs. We assessed patterns of clinical disease and viral load from different samples (nasopharyngeal and blood, urine, and stool samples), which were obtained once daily for 3 days from hospital admission, and once every 2 or 3 days until patient discharge. All samples were refrigerated and shipped to laboratories in the National Reference Center for Respiratory Viruses (The Institut Pasteur, Paris, and Hospices Civils de Lyon, Lyon, France), where RNA extraction, real-time RT-PCR, and virus isolation and titration procedures were done.

Findings

The patients were three men (aged 31 years, 48 years, and 80 years) and two women (aged 30 years and 46 years), all of Chinese origin, who had travelled to France from China around mid-January, 2020. Three different clinical evolutions are described: (1) two paucisymptomatic women diagnosed within a day of exhibiting symptoms, with high nasopharyngeal titres of SARS-CoV-2 within the first 24 h of the illness onset (5·2 and 7·4 log10 copies per 1000 cells, respectively) and viral RNA detection in stools; (2) a two-step disease progression in two young men, with a secondary worsening around 10 days after disease onset despite a decreasing viral load in nasopharyngeal samples; and (3) an 80-year-old man with a rapid evolution towards multiple organ failure and a persistent high viral load in lower and upper respiratory tract with systemic virus dissemination and virus detection in plasma. The 80-year-old patient died on day 14 of illness (Feb 14, 2020); all other patients had recovered and been discharged by Feb 19, 2020.

Interpretation

We illustrated three different clinical and biological types of evolution in five patients infected with SARS-CoV-2 with detailed and comprehensive viral sampling strategy. We believe that these findings will contribute to a better understanding of the natural history of the disease and will contribute to advances in the implementation of more efficient infection control strategies.

Funding

REACTing (Research & Action Emerging Infectious Diseases).

Le texte complet de cet article est disponible en PDF.

Plan


© 2020  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 20 - N° 6

P. 697-706 - juin 2020 Retour au numéro
Article précédent Article précédent
  • Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study
  • Haiyan Qiu, Junhua Wu, Liang Hong, Yunling Luo, Qifa Song, Dong Chen
| Article suivant Article suivant
  • Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial
  • Milagritos D Tapia, Samba O Sow, Birahim P Ndiaye, Khardiata D Mbaye, Aliou Thiongane, Cheikh T Ndour, Souleymane Mboup, Julie A Ake, Babajide Keshinro, Gideon A Akintunde, Thompson N Kinge, Guy Vernet, Jean Joel Bigna, Stephen Oguche, Kwadwo A Koram, Kwaku P Asante, Wayne R Hogrefe, Stephan Günther, Abdi Naficy, Iris De Ryck, Muriel Debois, Patricia Bourguignon, Erik Jongert, William R Ballou, Marguerite Koutsoukos, François Roman, Zaire EBola Research Alliance group, Senate Amusu, Leo Ayuk, Catherine Bilong, Owusu Boahen, Makhtar Camara, Fadima Cheick Haidara, Daouda Coly, Siry Dièye, David Dosoo, Melanie Ekedi, Irma Eneida Almeida Dos Santos, Seyram Kaali, Afoke Kokogho, Myron Levine, Nick Opoku, Seth Owusu-Agyei, Simon Pitmang, Fatima Sall, Moussa Seydi, Marcelo Sztein, Mathurin Tejiokem, Awa Traore, Marie-Astrid Vernet, Abena Kunadu Yawson

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.